PMV Pharmaceuticals Inc PMVP.OQ PMVP.O is expected to show no change in quarterly revenue when it reports results on March 2 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for PMV Pharmaceuticals Inc is for a loss of 40 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00, about 338% above its last closing price of $1.37
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.40 | -0.40 | -0.40 | Met | 0.6 |
Jun. 30 2025 | -0.38 | -0.38 | -0.41 | Missed | -7 |
Mar. 31 2025 | -0.38 | -0.37 | -0.34 | Beat | 9.2 |
Dec. 31 2024 | -0.39 | -0.38 | -0.45 | Missed | -18.2 |
Sep. 30 2024 | -0.36 | -0.35 | -0.37 | Missed | -5.4 |
Jun. 30 2024 | -0.35 | -0.35 | -0.02 | Beat | 94.3 |
Mar. 31 2024 | -0.35 | -0.36 | -0.30 | Beat | 16.8 |
Dec. 31 2023 | -0.38 | -0.39 | -0.31 | Beat | 19.7 |
This summary was machine generated February 27 at 14:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)